Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
boston
3
×
boston blog main
boston top stories
clinical trials
hepatitis b
3
×
life sciences
national blog main
national top stories
alexion pharmaceuticals
boehringer ingelheim
deals
fda
rna interference
san francisco blog main
san francisco top stories
aligos therapeutics
alnylam pharmaceutials
alnylam pharmaceuticals
arrowhead pharmaceuticals
baker brothers life sciences
benzodiazepine
biotech ipos
blackstone group
blepharitis
cavion
cephalgia
chronic hepatitis b virus
david goldstein
demodex blepharitis
depression
dicerna pharamceuticals
dicerna pharmaceuticals
eli lilly
epilepsy
essential tremor
eventide asset management
hepatitis b virus
hereditary transthyretin amyloidosis
horowitz group
What
medicines
dicerna
pharma
research
abandoning
ago
baggage
biotechs
caught
causing
central
cns
companies
cuts
deal
development
disease
disorder
drug
drugs
emerged
eye
free
gene
gets
hepatitis
intended
interference
ipos
kept
leads
long
nervous
pay
pharmaceuticals
praxis
precision
prep
producing
protein
Language
unset
Current search:
biotech
×
boston
×
" hepatitis b "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M